What’s New

We share news about new product features, our thoughts on recent developments at MedaSystems or in the industry at large. Scroll down for a chronological view, or jump to posts using the categories to the left.

Beyond Patient Access: What New Neuro-Oncology Research Reveals About AI and Real-World Evidence

New research presented at the 2026 Society for Neuro-Oncology Annual Meeting highlights how AI can transform real-world data from Expanded Access Programs into valuable clinical insights. Discover how AI-powered analysis can uncover treatment patterns, improve data consistency, and help pharmaceutical companies unlock the potential of real-world evidence to support clinical research and program oversight.

Read More

Why Excel and Email Are No Longer Enough for Global EAP and IIS Programs

As global EAP and IIS programs grow in scale and complexity, spreadsheets, email, and shared drives can create operational, security, and compliance risks. Discover why purpose-built, validated technology provides a more scalable, traceable, and controlled foundation for global programs.

Read More

Build vs. Buy in Expanded Access Programs: Finding the Right Balance for Patient Access

As expanded access and managed access programs become increasingly important components of patient access strategy, biopharmaceutical companies face a critical question: which capabilities should be developed internally, and which are best supported through external expertise and technology partners?

Read More

How Expanded Access Programs Are Evolving in 2026

For patients facing serious or life-threatening conditions, waiting for full regulatory approval of a promising therapy is often not an option. Expanded Access Programs (EAPs), sometimes referred to as compassionate use programs, have long provided a regulatory pathway for patients to receive investigational treatments outside of clinical trials.

Read More